← All stocks

aTYR PHARMA INC

ATYR Net buying

CIK 0001339970 #4704 in the set updated 19 Sep 2026

Bought (12 mo)

$961.43K

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$6.27K

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$6.27K

3 of 3 sales

Net

+$955.16K

+$955.16K against sales at will

By person

5 insiders · 6 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

SCHIMMEL PAUL

Director

$961.43K (3)

—

+$961.43K

779,143

0.7943%

$386.69K

—

Shukla Sanjay

President and CEO

—

$3.66K (1)

−$3.66K

153,553

0.1565%

$76.21K

+12.5%

Broadfoot Jill Marie

Chief Financial Officer

—

$1.52K (1)

−$1.52K

37,296

0.0380%

$18.51K

+14.4%

DENYES NANCY

General Counsel

—

$1.09K (1)

−$1.09K

33,124

0.0338%

$16.44K

+11.3%

Gross Jane A

Director

—

9,750

0.0099%

$4.84K

+62.5%

Individual transactions

Insider

Date

Role

Action

Price

Amount

DENYES NANCY

4 Feb 2026

General Counsel

Sell

1,118

$0.98

$1.09K

Broadfoot Jill Marie

4 Feb 2026

Chief Financial Officer

Sell

1,558

$0.98

$1.52K

Shukla Sanjay

4 Feb 2026

President and CEO

Sell

3,745

$0.98

$3.66K

Show all 6 transactions →

What was left out

Form 4 filings counted 14

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 3

Transactions with no price 0

Shares from compensation/vesting 16,812

History held since 15 Sep 2016